Skip to content

Efficacy Evaluation of the Activity of a Cosmetic Product (Topical Use) on Hair Regrowth vs Placebo

Efficacy Evaluation of the Activity of a Cosmetic Product (Topical Use) on Hair Regrowth vs Placebo

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03273504
Enrollment
24
Registered
2017-09-06
Start date
2017-07-14
Completion date
2017-10-30
Last updated
2018-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertrichosis

Brief summary

Aim of the study is to evaluate clinically and by non-invasive instrumental evaluations the activity on hair regrowth of a topical cosmetic product versus placebo (comparison within subjects)

Interventions

OTHERActapil Corpo Spray (SHEDIR PHARMA Srl - Italy)

The study product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the right or left leg (tibialis area) according to a randomisation list.

OTHERPlacebo

The placebo product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the controlateral leg (tibialis area) right or left leg according to a randomisation list.

Sponsors

Derming SRL
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* healthy volunteers * female sex * with hypertrichosis * agreeing not to perform epilation or scrub/peeling treatment on the test area (legs) during the week preceding the inclusion * good general state of health

Exclusion criteria

* pregnancy * lactation * subjects whose insufficient adhesion to the study protocol is foreseeable * sensitive skin * oral contraceptive therapy started less than 1 year * presence of varicose or capillary veins of surface * hormonal therapies able to influence hair growth. * presence of cutaneous disease on the tested area, as lesions, scars, malformations. * diabetes * endocrine disease * hepatic disorder * renal disorder * cardiac disorder * cancer. * farmacological topical treatment and surgery and/or medical treatment on the treated side performed in the last 3 months * systemic corticosteroids * aspirin or non-steroid anti-inflammatory drugs (FANS) * diuretic.

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline of the hair densityBaseline (T0), 1 month (T1), 3 months (T3)Hair density (hair number/mm2) is calculate by Image-Pro Plus software on the microscopic images captured with Dino-Lite (AnMo Electronics Corporation,Taiwan)
Change from baseline of the percentage of terminal hairBaseline (T0), 1 month (T1), 3 months (T3)Percentage of terminal hair (terminal hair has a diameter \>0.04 mm) is calculate by Image-Pro Plus software on the microscopic images captured with Dino-Lite (AnMo Electronics Corporation,Taiwan)
Change from baseline of the percentage of vellus hairBaseline (T0), 1 month (T1), 3 months (T3)Percentage of vellus hair (terminal hair has a diameter \<0.04 mm) is calculate by Image-Pro Plus software on the microscopic images captured with Dino-Lite (AnMo Electronics Corporation,Taiwan)
Change from baseline of hair regrowth speedBaseline (T0), 1 month (T1), 3 months (T3)Hair regrowth speed (mm/die) is calculate by Image-Pro Plus software on the microscopic images captured with Dino-Lite (AnMo Electronics Corporation,Taiwan)

Secondary

MeasureTime frameDescription
Change from baseline of superficial skin hydrationBaseline (T0), 1 month (T1), 3 months (T3)Skin electrical capacitance value is measured with Corneometer CM825 (Courage - Khazaka, Köln, Germany). The measure of the skin capacitance properties is an indirect expression of its hydration level.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026